Kazuhiro Seike
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuhiro Seike has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Chihiro Kosugi
Department of Surgery Teikyo University Chiba Medical Center Ichihara Chiba Japan
2 shared publications K. Koda
Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
2 shared publicationsKenji Oda
2 shared publicationsKimio Shimizu
2 shared publications- Masaru Miyazaki
Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Japan
2 shared publications A. Hirano
Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
1 shared publication
Latest Publications
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv178
Voice Trial-Results from a Multicenter Phase Ii Study of Assessment of Clinical Efficacy and Safety in Capecitabine Plus Intermittent Oxaliplatin Together with Bevacizumab As the First-Line Therapy for the Patients with Advanced Colorectal Cancer
Aim: The FOLFOX with bevacizumab regimen has been established as a standard first-line therapy for metastatic colorectal cancer (mCRC), and the OPTIMOX1 study suggested that a stop and go strategy for oxaliplatin reduced peripheral sensory neuropathy. We had already evaluated the efficacy of OPTIMOX1 plus bevacizumab in patients (pts) with mCRC (CRAFT study, Tezuka et al, Invest New Drugs 2013). CapeOx is one of the standard treatments for mCRC that has been proven to be as effective as the FOLFOX regimen. Thus we assessed the efficacy and safety of the combination of intermittent CapeOx + Bevacizumab as a first-line therapy in patients with mCRC in this trial. Methods: Eligibility criteria included ECOG PS: 0–1, no peripheral neuropathy (2, capecitabine 2000mg/m2 + bevacizumab 7.5mg/kg) q3 weeks for 5 cycles, maintenance without oxaliplatin for 5 cycles, and reintroduction CapeOX + bevacizumab for 5 cycles until progression. Primary endpoint was progression-free survival (PFS). Results: Between March 2011 and August 2013, 55 pts were enrolled. Baseline characteristics were median age of 67 years (range, 20–83); PS 0/1 (49/6 pts); male/female(33/22 pts), colon/rectum (28/27pts) and metastatic lesion liver/lung/lymph nodes (32/18/21 pts). A total of 47 pts were evaluated as Par Protocol Set population. 38 pts moved from initial CapeOX to maintenance capecitabine. 20 pts moved to CapeOx reintroduction. Median PFS was 12.4 months (95%CI, 7.7–17.1) and Median TTF was 8.3 months (95%CI, 4.5–12.1). Best overall response rate was 50.9%. Median capecitabine courses were 5 cycles (range 1–5). Oxaliplatin reintroduction rate was 52%. The causes of reintroduction failure were disease progression (3 pts), successful liver resection (2 pts), peripheral sensory neuropathy grade 2 (1 pt). Main grade 3/4 toxicities: neutropenia, anemia, peripheral neuropathy, hand-foot syndrome, and hypertension in 1 patient. Conclusions: This study met its primary endpoint PFS. It was longer than the CRAFT study. CapeOx with intermittent oxaliplatin is indicated to reduce incidence of severe neutropenia and peripheral sensory neuropathy. The results suggested that our treatment strategy was well tolerated and effective for first-line therapy in mCRC, and maintenance of duration for 5 cycles was reasonable. Disclosure: All authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv178
Voice Trial-Results from a Multicenter Phase Ii Study of Assessment of Clinical Efficacy and Safety in Capecitabine Plus Intermittent Oxaliplatin Together with Bevacizumab As the First-Line Therapy for the Patients with Advanced Colorectal Cancer
Aim: The FOLFOX with bevacizumab regimen has been established as a standard first-line therapy for metastatic colorectal cancer (mCRC), and the OPTIMOX1 study suggested that a stop and go strategy for oxaliplatin reduced peripheral sensory neuropathy. We had already evaluated the efficacy of OPTIMOX1 plus bevacizumab in patients (pts) with mCRC (CRAFT study, Tezuka et al, Invest New Drugs 2013). CapeOx is one of the standard treatments for mCRC that has been proven to be as effective as the FOLFOX regimen. Thus we assessed the efficacy and safety of the combination of intermittent CapeOx + Bevacizumab as a first-line therapy in patients with mCRC in this trial. Methods: Eligibility criteria included ECOG PS: 0–1, no peripheral neuropathy (2, capecitabine 2000mg/m2 + bevacizumab 7.5mg/kg) q3 weeks for 5 cycles, maintenance without oxaliplatin for 5 cycles, and reintroduction CapeOX + bevacizumab for 5 cycles until progression. Primary endpoint was progression-free survival (PFS). Results: Between March 2011 and August 2013, 55 pts were enrolled. Baseline characteristics were median age of 67 years (range, 20–83); PS 0/1 (49/6 pts); male/female(33/22 pts), colon/rectum (28/27pts) and metastatic lesion liver/lung/lymph nodes (32/18/21 pts). A total of 47 pts were evaluated as Par Protocol Set population. 38 pts moved from initial CapeOX to maintenance capecitabine. 20 pts moved to CapeOx reintroduction. Median PFS was 12.4 months (95%CI, 7.7–17.1) and Median TTF was 8.3 months (95%CI, 4.5–12.1). Best overall response rate was 50.9%. Median capecitabine courses were 5 cycles (range 1–5). Oxaliplatin reintroduction rate was 52%. The causes of reintroduction failure were disease progression (3 pts), successful liver resection (2 pts), peripheral sensory neuropathy grade 2 (1 pt). Main grade 3/4 toxicities: neutropenia, anemia, peripheral neuropathy, hand-foot syndrome, and hypertension in 1 patient. Conclusions: This study met its primary endpoint PFS. It was longer than the CRAFT study. CapeOx with intermittent oxaliplatin is indicated to reduce incidence of severe neutropenia and peripheral sensory neuropathy. The results suggested that our treatment strategy was well tolerated and effective for first-line therapy in mCRC, and maintenance of duration for 5 cycles was reasonable. Disclosure: All authors have declared no conflicts of interest.
- Open Access
- 17 April 2010
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 8 (1) , 29
Advanced moderately differentiated neuroendocrine carcinoma of the rectum with favorable prognosis by postoperative chemoradiation
Rectal neuroendocrine carcinoma is rare with poor prognosis. We report herein a case of advanced moderately differentiated neuroendocrine carcinoma of the rectum with relatively favorable prognosis treated by postoperative adjuvant chemoradiation therapy. A 58-year-old Japanese female was referred and colonofiberscopy revealed an easy-bleeding irregular tumor in the lower rectum, which was pathologically diagnosed as a neuroendocrine carcinoma. Surgical treatment consisted of abdominoperineal resection and lymph node dissection. The tumor invaded deeply into perirectal tissues, and 9 of 11 lymph node metastases were observed. Immunohistochemically, chromogranin A showed diffuse and strong staining, and the MIB-1 labeling index was 18.3 ± 5.6, supporting the high proliferation of the tumor. Some nucleus of the tumor showed positive staining for p21/WAF1. A total dose of 46 Gy of radiotherapy was delivered with 800 mg of daily oral doxifluridine. At 5 years post-surgery, the patient demonstrated no clinical evidence of intrapelvic recurrence or distant metastases.
- 17 April 2010
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 8 (1) , 29
Open AccessAdvanced moderately differentiated neuroendocrine carcinoma of the rectum with favorable prognosis by postoperative chemoradiation
Rectal neuroendocrine carcinoma is rare with poor prognosis. We report herein a case of advanced moderately differentiated neuroendocrine carcinoma of the rectum with relatively favorable prognosis treated by postoperative adjuvant chemoradiation therapy. A 58-year-old Japanese female was referred and colonofiberscopy revealed an easy-bleeding irregular tumor in the lower rectum, which was pathologically diagnosed as a neuroendocrine carcinoma. Surgical treatment consisted of abdominoperineal resection and lymph node dissection. The tumor invaded deeply into perirectal tissues, and 9 of 11 lymph node metastases were observed. Immunohistochemically, chromogranin A showed diffuse and strong staining, and the MIB-1 labeling index was 18.3 ± 5.6, supporting the high proliferation of the tumor. Some nucleus of the tumor showed positive staining for p21/WAF1. A total dose of 46 Gy of radiotherapy was delivered with 800 mg of daily oral doxifluridine. At 5 years post-surgery, the patient demonstrated no clinical evidence of intrapelvic recurrence or distant metastases.
- 21 May 2009
- Vol. 56 (89) , 111-5
Gender differences in pelvic anatomy and effects on rectal cancer surgery.
The male pelvis is said to be narrower and deeper than the female pelvis. The present study aimed to evaluate anatomical differences in the pelvis between genders, and to analyze effects on rectal cancer surgery. Gender differences in pelvic anatomy were evaluated using computed tomography in 78 Japanese patients who had received low anterior resection for rectal cancer. Factors affecting operative duration and intraoperative blood loss were analyzed for both low anterior resection and ultra-low anterior resection. Pelvic capacity was significantly lower in males (460.0 +/- 16.7 cm3) than in females (634.8 +/- 22.0 cm3; p < 0.0001), and level of the levator ani compared to the upper edge of the pubis was significantly lower in males than in females. Surgical parameters in ultra-low anterior resection were affected by level of the levator ani, tumor volume and tumor height compared to the upper edge of the pubis, not by tumor height above anal verge. The pelvis was narrower and deeper in males than in females. Obtaining good visualization is critical particularly in performing ultra-low anterior resection against a large tumor located below the upper edge of the pubis in a patient who has deep pelvic floor.
- 21 May 2009
- Vol. 56 (89) , 111-5
Gender differences in pelvic anatomy and effects on rectal cancer surgery.
The male pelvis is said to be narrower and deeper than the female pelvis. The present study aimed to evaluate anatomical differences in the pelvis between genders, and to analyze effects on rectal cancer surgery. Gender differences in pelvic anatomy were evaluated using computed tomography in 78 Japanese patients who had received low anterior resection for rectal cancer. Factors affecting operative duration and intraoperative blood loss were analyzed for both low anterior resection and ultra-low anterior resection. Pelvic capacity was significantly lower in males (460.0 +/- 16.7 cm3) than in females (634.8 +/- 22.0 cm3; p < 0.0001), and level of the levator ani compared to the upper edge of the pubis was significantly lower in males than in females. Surgical parameters in ultra-low anterior resection were affected by level of the levator ani, tumor volume and tumor height compared to the upper edge of the pubis, not by tumor height above anal verge. The pelvis was narrower and deeper in males than in females. Obtaining good visualization is critical particularly in performing ultra-low anterior resection against a large tumor located below the upper edge of the pubis in a patient who has deep pelvic floor.
- 3 November 2006
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 22 (6) , 689-697
Laser Doppler assessment of the influence of division at the root of the inferior mesenteric artery on anastomotic blood flow in rectosigmoid cancer surgery
The aim of this study is to evaluate the influence of dividing the inferior mesenteric artery (IMA) and preserving the left colic artery (LCA) on rectosigmoid cancer surgery.
- 3 November 2006
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 22 (6) , 689-697
Laser Doppler assessment of the influence of division at the root of the inferior mesenteric artery on anastomotic blood flow in rectosigmoid cancer surgery
The aim of this study is to evaluate the influence of dividing the inferior mesenteric artery (IMA) and preserving the left colic artery (LCA) on rectosigmoid cancer surgery.
- 1 January 2003
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 38 (4) , 387-391
Relevance of Abdominal Gas Analysis and Transit Study after Colorectal Cancer Surgery
Background: Colon gas volume analysis using abdominal radiographs is an objective and reproducible method for evaluating functional bowel disorders. The aim of this study was to clarify the relevance of colon gas distribution and transit time in rectosigmoid cancer patients after surgery. Methods: Segmental colon gas volume score was calculated using plain abdominal radiography and evaluated in 40 patients who had undergone sphincter-saving resection. Segmental colonic transit time was analysed using radiopaque markers in the same patients. Results: Transit times in the right colon (RCT) were 15.3 ± 1.1 h and in the left colon (LCT) 11.2 ± 1.1 h. Gas volume scores in the RCS and LCS were 1.10 ± 0.13% and 1.06 ± 0.14%, respectively. Neither colonic transit time nor colon gas volume score correlated with the operation methods for rectosigmoid colon cancer. A positive correlation of RCS and a negative correlation of LCS/RCS with ageing were noted in male patients but not in female patients. There was no correlation between RCT and RCS (r = 0.028); however, LCT correlated with LCS (r = 0.318, P < 0.05). The ratio of colonic transit time (LCT/RCT) was 0.84 ± 0.10, while that of colon gas volume score (LCS/RCS) was 1.29 ± 0.21. There was a significant correlation between LCT/RCT and LCS/RCS (r = 0.541, P < 0.001). Conclusions: Analysis of colon gas volume is useful for evaluating colonic transit time in rectosigmoid cancer patients after sphincter-saving surgery.
- 1 January 2003
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 38 (4) , 387-391
Relevance of Abdominal Gas Analysis and Transit Study after Colorectal Cancer Surgery
Background: Colon gas volume analysis using abdominal radiographs is an objective and reproducible method for evaluating functional bowel disorders. The aim of this study was to clarify the relevance of colon gas distribution and transit time in rectosigmoid cancer patients after surgery. Methods: Segmental colon gas volume score was calculated using plain abdominal radiography and evaluated in 40 patients who had undergone sphincter-saving resection. Segmental colonic transit time was analysed using radiopaque markers in the same patients. Results: Transit times in the right colon (RCT) were 15.3 ± 1.1 h and in the left colon (LCT) 11.2 ± 1.1 h. Gas volume scores in the RCS and LCS were 1.10 ± 0.13% and 1.06 ± 0.14%, respectively. Neither colonic transit time nor colon gas volume score correlated with the operation methods for rectosigmoid colon cancer. A positive correlation of RCS and a negative correlation of LCS/RCS with ageing were noted in male patients but not in female patients. There was no correlation between RCT and RCS (r = 0.028); however, LCT correlated with LCS (r = 0.318, P < 0.05). The ratio of colonic transit time (LCT/RCT) was 0.84 ± 0.10, while that of colon gas volume score (LCS/RCS) was 1.29 ± 0.21. There was a significant correlation between LCT/RCT and LCS/RCS (r = 0.541, P < 0.001). Conclusions: Analysis of colon gas volume is useful for evaluating colonic transit time in rectosigmoid cancer patients after sphincter-saving surgery.